Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering.
Tampa, FL, 33634